Current incidence and residual risk of hepatitis B infection among blood donors in the United States
Article first published online: 28 APR 2009
© 2009 American Association of Blood Banks
Volume 49, Issue 8, pages 1609–1620, August 2009
How to Cite
Zou, S., Stramer, S. L., Notari, E. P., Kuhns, M. C., Krysztof, D., Musavi, F., Fang, C. T. and Dodd, R. Y. (2009), Current incidence and residual risk of hepatitis B infection among blood donors in the United States. Transfusion, 49: 1609–1620. doi: 10.1111/j.1537-2995.2009.02195.x
- Issue published online: 30 JUL 2009
- Article first published online: 28 APR 2009
- Received for publication December 29, 2008; revision received February 20, 2009; and accepted February 20, 2009.
BACKGROUND: This study used two approaches to estimate the current incidence of hepatitis B virus (HBV) in a US donor population.
METHODS: HBV incidence was estimated through the hepatitis B surface antigen (HBsAg) yield approach and the seroconversion method. Residual risk was estimated by the incidence–window period model. HBsAg yield refers to an HBsAg confirmed-positive, antibody against hepatitis B core antigen (anti-HBc)–nonreactive donation, adjusted for false-positive neutralization results. The number of HBsAg-seroconverting repeat donors divided by total number of person-years of evaluation or the HBsAg yield rate divided by HBsAg yield window gave rise to incidence estimates.
RESULTS: The seroconversion and the yield approach, respectively, gave an incidence estimate of 3.41 or 3.43 per 105 person-years. Using a revised infectious window period of 38 or 30 days for current HBsAg assays, the current residual risk for HBV was respectively estimated for 2006 to 2008 at 1 in 282,000 or 1 in 357,000 donations from the seroconversion approach and 1 in 280,000 or 1 in 355,000 donations from the yield approach. With the same database and methods, this is a decrease from 1 in 86,000 to 1 in 110,000 observed in 1997 to 1999.
CONCLUSIONS: Current HBV incidence and residual risk are lower than earlier estimates, especially in the youngest donors, but remain higher in the absence of HBV nucleic acid test than those for human immunodeficiency virus or hepatitis C virus (HCV). In addition to the exclusion of HBsAg false-positive donors, the reduction could reflect shortened window periods and decreased incidence rates due to vaccination or other reasons.